Search Results - "Sevillano Fernandez, Elena"

Prognostic Value and Clinical Significance of FGFR Genomic Alterations (GAs) in Metastatic Urothelial Cancer Patients by Sevillano Fernández, Elena, Madurga de Lacalle, Rodrigo, Rodriguez Moreno, Juan Francisco, Barquín García, Arantzazu, Yagüe Fernández, Mónica, Navarro Alcaraz, Paloma, Barba Llacer, María, Quiralte Pulido, Miguel, García-Donás Jiménez, Jesús

“…Fibroblast growth factor receptor (FGFR) genomic alterations (GAs) represent an actionable target, key to the pathogenesis of some urothelial cancers (UCs)…”
Get full text

Proteomic profiles of peritoneal fluid-derived small extracellular vesicles correlate with patient outcome in ovarian cancer by Quiralte, Miguel, Barquín, Arantzazu, Yagüe-Fernández, Mónica, Navarro, Paloma, Grazioso, Tatiana P, Sevillano-Fernández, Elena, Rodriguez-Moreno, Juan F, Balarezo-Saldivar, Alejandra, Peinado, Héctor, Izquierdo, Elena, Millán, Carlos, López-Carrasco, Irene, Prieto, Mario, Madurga, Rodrigo, Fernández-Miranda, Ismael, Ruiz-Llorente, Sergio, García-Donas, Jesús

“…Cancer-derived small extracellular vesicles (sEVs) are capable of modifying the tumor microenvironment and promoting tumor progression. Ovarian cancer (OvCa)…”
Get full text

MEK inhibitor sensitivity in BRAF fusion-driven prostate cancer by Fenor, María Dolores, Ruiz-Llorente, Sergio, Rodríguez-Moreno, Juan Francisco, Caleiras, Eduardo, Torrego, Juan Carlos, Sevillano-Fernández, Elena, Navarro, Paloma, Yagüe-Fernández, Mónica, Amarilla-Quintana, Sandra, Barquín, Arantzazu, García-Donas, Jesús

“…Purpose The identification of subpopulations harboring druggable targets has become a major step forward in the subclassification of solid tumors into small…”
Get full text

763 Expanded and activated TILs kill tumor cells enabling IO compound assays by Pennacchi, Paula Comune, Navarro, Paloma, Navas, Verónica García, García, Arántzazu Barquín, Fernández, Elena Sevillano, Llorente, Sergio Ruiz, Rodriguez, Juan Francisco, Yagüe, Monica, Ballesteros, Joan, Primo, Daniel, Donas Jimenez, Jesus Garcia

“…BackgroundThe Tumor Microenvironment (TME) has a key role in solid tumor therapy screening. We have developed a 3D ex vivo immunosuppressive assay mimicking…”
Get full text

Infigratinib Versus Placebo for Patients with High-risk Resected Urothelial Cancer Bearing an FGFR3 Genomic Alteration: Results from the PROOF302 Phase 3 Trial by Pal, Sumanta K., Grivas, Petros, Gupta, Shilpa, Dizman, Nazli, Zengin, Zeynep, Valderrama, Begona P., Rodriguez-Vida, Alejo, Roghmann, Florian, Sevillano Fernandez, Elena, Matin, Surena F., Loriot, Yohann, Sridhar, Srikala S., Sonpavde, Guru, Fleming, Mark T., Lerner, Seth P., Bellmunt, Joaquim, Master, Viraj, Tripathi, Abhishek, Davis, Kim, van Veenhuyzen, David, Weng, Richard, Daneshmand, Siamak

Get full text

Preliminary analysis of a phase II, multicenter, randomized, active-control study to evaluate the efficacy and safety of eganelisib (IPI 549) in combination with nivolumab compared to nivolumab monotherapy in patients with advanced urothelial carcinoma by Tomczak, Piotr, Popovic, Lazar, Barthelemy, Philippe, Janicic, Aleksander, Sevillano Fernandez, Elena, Borchiellini, Delphine, Aglietta, Massimo, Maroto, José, Carnot, Aurelien, O'Connell, Brenda, ZIZLSPERGER, NORA, Zhang, Halle Huihong, Valderrama, Begoña P.

“…Abstract only 436 Background: Inhibition of the PD-1 pathway has demonstrated clinical benefit in metastatic urothelial carcinoma (mUC); however, response…”
Get full text

Retrospective study to assess the efficacy and safety of checkpoint inhibitors in advanced urothelial carcinoma in real-world setting by Sevillano Fernandez, Elena, Puente, Javier, Vidal, Natalia, Pinto, Alvaro, Garcia Sanchez, Lourdes, Fiorini, Aldo, Chara Velarde, Luis Enrique, Ariza, Irene Nalda, Cassinello, Javier, Rodriguez, Angel, Galvan Ruiz, Saray, Rodriguez-Moreno, Juan Francisco, Barquin, Arantzazu, Ruiz, Sergio, Navarro, Paloma, Yagüe, Monica, Grande, Enrique, García-Donas, Jesús

“…Abstract only e17043 Background: Checkpoint Inhibitors (CPI) have become a new standard of treatment in advanced urothelial carcinoma. However, little is known…”
Get full text

Abstract 5288: Mechanisms of resistance to FGFR inhibitors in urothelial cancer cell lines and patients harboring FGFR3 alterations and strategies to overcome it by Ruiz-Llorente, Sergio, Fernández-Sevillano, Elena, Navarro, Paloma, Rodríguez-Moreno, Juan Francisco, Barquín-García, Arantzazu, Amarilla-Quintana, Sandra, Yagüe-Fernández, Mónica, Roldan-Romero, Juan María, Martín, Raquel, Rodriguez-Antona, Cristina, García-Donas, Jesús

“…Abstract Introduction The Fibroblast Growth Factor Receptor (FGFR) has become a key target in urothelial cancer. The FGFR inhibitor (FGFRi) erdafitinib has…”
Get full text